Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 5:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 129 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Testosterone Oral Clear all
Completed No phase listed Observational Accepts healthy volunteers

Sensitivity of Short and Long Allele Carriers of the 5-HTTLPR to Environmental Threat Post Hydrocortisone Administration

NCT01710202
View directory record Official record
Conditions
Major Depressive Disorder, Anxiety Disorders
Interventions
Hydrocortisone
Drug
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
2
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 19, 2015 · Synced Sep 2, 2026, 5:22 AM EDT
Completed Phase 2 Interventional Results available

Pilot Pharmacokinetic Study of Oral Testosterone Ester Formulations in Hypogonadal Men

NCT02697188
View directory record Official record
Conditions
Hypogonadism
Interventions
Testosterone undecanoate, Testosterone enanthate
Drug
Lead sponsor
Clarus Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
2
States / cities
Los Angeles, California • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 31, 2018 · Synced Sep 2, 2026, 5:22 AM EDT
Suspended Not applicable Interventional

Insulin Sensitivity in Men With the Metabolic Syndrome

NCT00433173
View directory record Official record
Conditions
Metabolic Syndrome
Interventions
intravenous glucose tolerance test, testosterone, anastrozole, goserelin acetate implant, aerobic capacity (VO2 Max), MRI, muscle biopsy, measurement of resting metabolic rate (energy expenditure), Dual energy x-ray absorptiometry, Fasting oral glucose tolerance test
Procedure · Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
50 Years to 75 Years · Male only
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
2
States / cities
Baltimore, Maryland • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 1, 2010 · Synced Sep 2, 2026, 5:22 AM EDT
Completed Phase 2 Interventional

A Study to Assess the Efficacy, Safety, and Tolerability of Oral LPCN 1148 in Male Subjects With Cirrhosis of the Liver and Sarcopenia

NCT04874350
View directory record Official record
Conditions
Liver Cirrhosis, Sarcopenia
Interventions
LPCN 1148, Placebo
Drug
Lead sponsor
Lipocine Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
10
States / cities
Scottsdale, Arizona • Los Angeles, California • San Francisco, California + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2024 · Synced Sep 2, 2026, 5:22 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Compromised Microcirculation in Women With Polycystic Ovary Syndrome

NCT00757185
View directory record Official record
Conditions
Polycystic Ovary Syndrome
Interventions
ganirelix acetate, methyl testosterone
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 3, 2016 · Synced Sep 2, 2026, 5:22 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Hypoglycemia Associated Autonomic Failure in Type 1 Diabetes Mellitus

NCT00607646
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Dehydroepiandrosterone, Placebo
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 45 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 11, 2019 · Synced Sep 2, 2026, 5:22 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Polycystic Ovary Syndrome (PCOS) and Sleep Apnea

NCT00203996
View directory record Official record
Conditions
Polycystic Ovary Syndrome, Obstructive Sleep Apnea
Interventions
continuous positive airway pressure (CPAP), depot leuprolide plus estrogen/progestin replacement, pioglitazone, REM frag, SWS supp
Device · Drug · Procedure
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 40 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2008
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 20, 2023 · Synced Sep 2, 2026, 5:22 AM EDT
Recruiting Phase 2 Interventional

Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer

NCT06059118
View directory record Official record
Conditions
Prostate Cancer
Interventions
DFMO, testosterone cypionate, Luteinizing hormone-releasing hormone (LHRH) analogue, Enzalutamide
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Sep 2, 2026, 5:22 AM EDT
Terminated Early Phase 1 Interventional

Pilot of Osanetant to Reduce Testosterone in Men With Adenocarcinoma of the Prostate

NCT05607342
View directory record Official record
Conditions
Prostate Adenocarcinoma
Interventions
Osanetant
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older · Male only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 20, 2024 · Synced Sep 2, 2026, 5:22 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Comparing Direct and Indirect Detection Methods of Multiple Routes of Testosterone Administration

NCT06393634
View directory record Official record
Conditions
Healthy
Interventions
Testosterone injection, Testosterone gel, Testosterone Oral
Drug
Lead sponsor
Sports Medicine Research and Testing Laboratory
Industry
Eligibility
18 Years to 60 Years · Male only
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
South Jordan, Utah
Source: ClinicalTrials.gov public record
Updated Dec 2, 2024 · Synced Sep 2, 2026, 5:22 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

PROS-1-Male Hormonal Contraceptive Regimens on Prostate Tissue

NCT00490555
View directory record Official record
Conditions
Healthy
Interventions
Testosterone gel, Dutasteride, Depo-Medroxyprogesterone (DMPA), Placebo Testosterone gel, Placebo dutasteride, Placebo DMPA
Drug · Other
Lead sponsor
University of Washington
Other
Eligibility
25 Years to 55 Years · Male only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 14, 2013 · Synced Sep 2, 2026, 5:22 AM EDT
Terminated Phase 2 Interventional Results available

Hypogonadism in Young Men With Type 2 Diabetes

NCT01155518
View directory record Official record
Conditions
Hypogonadotropic Hypogonadism, Type 2 Diabetes
Interventions
testosterone, clomiphene, placebo
Drug
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years to 40 Years · Male only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Oct 3, 2019 · Synced Sep 2, 2026, 5:22 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Feasibility of an Oral Intervention for Sexual Health in Transgender Men

NCT06470906
View directory record Official record
Conditions
Vaginal Dysbiosis, Vaginal Disease, Molecular-bacterial Vaginosis
Interventions
Probiotic Group, Placebo Group
Dietary Supplement
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 45 Years · Male only
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated May 8, 2025 · Synced Sep 2, 2026, 5:22 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Oral Androgens in Man-3 (ORAL T-3) Pharmacokinetics of Oral Testosterone

NCT00161421
View directory record Official record
Conditions
Contraception, Hypogonadism
Interventions
Oral Testosterone, Leuprolide (Lupron), Dutasteride
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 50 Years · Male only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 18, 2008 · Synced Sep 2, 2026, 5:22 AM EDT
Completed Phase 2 Interventional Results available

Pharmacokinetic Study to Determine Time to Steady-state

NCT00911586
View directory record Official record
Conditions
Male Hypogonadism, Primary Hypogonadism, Secondary Hypogonadism
Interventions
Testosterone undecanoate
Drug
Lead sponsor
Clarus Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years · Male only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Dec 10, 2020 · Synced Sep 2, 2026, 5:22 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

TRADE-Testosterone Replacement and Dutasteride Effectiveness

NCT00194675
View directory record Official record
Conditions
Hypogonadism, Benign Prostatic Hyperplasia
Interventions
Dutasteride, Testosterone gel, Placebo dutasteride
Drug
Lead sponsor
University of Washington
Other
Eligibility
50 Years and older · Male only
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2010
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 4, 2017 · Synced Sep 2, 2026, 5:22 AM EDT
Completed Phase 3 Interventional

Study of Transdermal Testosterone Patches in Naturally Menopausal Women With Low Libido

NCT00338312
View directory record Official record
Conditions
Hypoactive Sexual Desire Disorder
Interventions
Testosterone Transdermal System, Placebo patch
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
40 Years to 70 Years · Female only
Enrollment
610 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 16, 2013 · Synced Sep 2, 2026, 5:22 AM EDT
Completed Phase 2 Interventional Results available

Oral Testosterone for the Treatment of Hypogonadism in Males

NCT02222558
View directory record Official record
Conditions
Hypogonadism
Interventions
TSX-002
Drug
Lead sponsor
TesoRx Pharma, LLC
Industry
Eligibility
18 Years to 70 Years · Male only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated May 29, 2016 · Synced Sep 2, 2026, 5:22 AM EDT
Completed Phase 2 Interventional Results available

An Observational Study of Continuous Oral Dosing of Abiraterone Acetate in Castration-Resistant Prostate Cancer Patients Evaluating Androgens and Steroid Metabolites in Bone Marrow Plasma

NCT00544440
View directory record Official record
Conditions
Prostate Neoplasms
Interventions
Abiraterone acetate, Prednisone
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 16, 2014 · Synced Sep 2, 2026, 5:22 AM EDT
Terminated Phase 1 Interventional

Effect of Varying Testosterone Levels on Insulin Sensitivity in Men With Idiopathic Hypogonadotropic Hypogonadism (IHH)

NCT03118479
View directory record Official record
Conditions
Hypogonadotropic Hypogonadism, Kallmann Syndrome
Interventions
Anastrozole Pill, Testosterone, Placebo Oral Tablet
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older · Male only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 17, 2017 · Synced Sep 2, 2026, 5:22 AM EDT
Completed Phase 4 Interventional Results available

Patient Satisfaction After Switching to Oral Testosterone Undecanoate

NCT04983940
View directory record Official record
Conditions
Testosterone Deficiency
Interventions
Jatenzo
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 65 Years · Male only
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 13, 2023 · Synced Sep 2, 2026, 5:22 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Trial of Testosterone Undecanoate

NCT01765179
View directory record Official record
Conditions
Male Hypogonadism
Interventions
Oral testosterone undecanoate
Drug
Lead sponsor
Clarus Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years · Male only
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
27
States / cities
Birmingham, Alabama • Huntsville, Alabama • Glendale, Arizona + 22 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2017 · Synced Sep 2, 2026, 5:22 AM EDT
Not yet recruiting Phase 2Phase 3 Interventional

Testosterone Therapy With or Without Finasteride After Spinal Cord Injury: TRT-SCI Trial

NCT07742553
View directory record Official record
Conditions
Spinal Cord Injury, Spinal Cord Injuries, Injuries, Spinal Cord, Spinal Cord Contusion, Spinal Cord Trauma, Trauma, Nervous System, Wounds and Injuries, Spinal Cord Compression, Nervous System Diseases, Spinal Cord Diseases, Gonadal Disorders, Endocrine System Diseases, Hypogonadism, Genital Diseases, Male
Interventions
testosterone cypionate, finasteride, placebo injection, placebo pill
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older · Male only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2032
U.S. locations
4
States / cities
Aurora, Colorado • Gainesville, Florida • Tampa, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Sep 2, 2026, 5:22 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

The Effects of Castration on the Pharmacokinetics of Zolpidem After Single Dose Administration In Men With Prostate Cancer Undergoing Androgen Deprivation Therapy Compared to Normal Healthy Females

NCT03436745
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Zolpidem, ECG
Drug · Diagnostic Test
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Sep 2, 2026, 5:22 AM EDT